View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2015	Apr. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		125,763,616
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 13,199,000	$ 14,622,000
Accounts receivable, net of reserves of $945,000 and of $1,523,000 in 2015 and 2014, respectively	704,000	1,243,000
Inventories, net	4,614,000	4,829,000
Other current assets	1,344,000	992,000
Total current assets	19,861,000	21,686,000
Property and equipment, net	1,778,000	1,583,000
Restricted cash and cash equivalents	350,000	350,000
Other assets	1,785,000	1,763,000
Intangibles, net	9,350,000	9,415,000
Goodwill	3,922,000	3,922,000
Total assets	37,046,000	38,719,000
Current liabilities:
Accounts payable and accrued expenses	5,614,000	5,546,000
Current portion of long-term obligations, net of discount	10,000,000	7,363,000
Joint venture purchase obligation	3,088,000	3,008,000
Total current liabilities	18,702,000	15,917,000
Deferred revenues	118,000	112,000
Warrant liability, long-term	25,237,000	9,793,000
Long-term deferred rent and other	507,000	558,000
Long-term obligations, net of discount, less current portion	15,677,000	18,041,000
Total liabilities	60,241,000	44,421,000
Commitments and contingencies
Stockholders' deficit:
Series A 3.6% convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 13,500 shares issued; 325 and 5,311 outstanding in 2015 and 2014, respectively	0	0
Common stock, $0.001 par value; 290,000,000 shares authorized; 114,097,357 and 99,348,377 shares issued and outstanding in 2015 and 2014, respectively	114,000	99,000
Additional paid-in capital	336,186,000	331,772,000
Accumulated other comprehensive income	736,000	700,000
Accumulated deficit	(360,231,000)	(338,273,000)
Total stockholders' deficit	(23,195,000)	(5,702,000)
Total liabilities and stockholders' deficit	$ 37,046,000	$ 38,719,000

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Accounts receivable, reserves	$ 945,000	$ 1,523,000
Stockholders' deficit:
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	290,000,000	290,000,000
Common stock, shares issued (in shares)	114,097,357	99,348,377
Common stock, shares outstanding (in shares)	114,097,357	99,348,377
Series A Preferred Stock [Member]
Stockholders' deficit:
Convertible preferred stock (in hundredths)	3.60%	3.60%
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	13,500	13,500
Preferred stock, shares outstanding (in shares)	325	5,311

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) [Abstract]
Product revenues	$ 902,000	$ 1,031,000
Cost of product revenues	598,000	421,000
Gross profit	304,000	610,000
Development revenues:
Government contracts and other	1,444,000	403,000
Operating expenses:
Research and development	3,963,000	4,292,000
Sales and marketing	839,000	1,928,000
General and administrative	2,499,000	4,340,000
Change in fair value of warrants	15,444,000	0
Total operating expenses	22,745,000	10,560,000
Operating loss	(20,997,000)	(9,547,000)
Other income (expense):
Interest income	1,000	2,000
Interest expense	(1,072,000)	(941,000)
Other income, net	110,000	86,000
Total other expense	(961,000)	(853,000)
Net loss	(21,958,000)	(10,400,000)
Beneficial conversion feature for convertible preferred stock	(661,000)	0
Net loss allocable to common stock holders	$ (22,619,000)	$ (10,400,000)
Basic and diluted net loss per share allocable to common stockholders (in dollars per share)	$ (0.21)	$ (0.14)
Basic and diluted weighted average shares used in calculating net loss per share allocable to common stockholders (in shares)	106,208,857	74,102,396
Comprehensive loss:
Net loss	$ (21,958,000)	$ (10,400,000)
Other comprehensive income (loss) - foreign currency translation adjustments	36,000	(50,000)
Comprehensive loss	$ (21,922,000)	$ (10,450,000)

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	$ (21,958,000)	$ (10,400,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	213,000	160,000
Amortization of deferred financing costs and debt discount	257,000	281,000
Joint venture acquisition obligation accretion	203,000	0
Provision for doubtful accounts	0	465,000
Change in fair value of warrants	15,444,000	0
Stock-based compensation expense	459,000	687,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	546,000	49,000
Inventories	100,000	(551,000)
Other current assets	(470,000)	(172,000)
Other assets	68,000	379,000
Accounts payable and accrued expenses	138,000	351,000
Deferred revenues	21,000	(165,000)
Long-term deferred rent	(51,000)	(46,000)
Net cash used in operating activities	(5,030,000)	(8,962,000)
Cash flows from investing activities:
Purchases of property and equipment	(187,000)	(287,000)
Expenditures for intellectual property	0	(155,000)
License agreement termination fee	0	(200,000)
Net cash used in investing activities	(187,000)	(642,000)
Cash flows from financing activities:
Joint venture purchase payments	(123,000)	(2,138,000)
Proceeds from exercise of employee stock options and warrants	0	33,000
Proceeds from sale of common stock, net	3,974,000	9,000,000
Dividends paid on preferred stock	(72,000)	0
Net cash provided by financing activities	3,779,000	6,895,000
Effect of exchange rate changes on cash and cash equivalents	15,000	3,000
Net decrease in cash and cash equivalents	(1,423,000)	(2,706,000)
Cash and cash equivalents at beginning of period	14,622,000	15,506,000
Cash and cash equivalents at end of period	13,199,000	12,800,000
Cash paid during period for:
Interest	612,000	659,000
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock into common stock	10,000	0
Declared dividend related to preferred stock	$ 3,000	$ 0

Basis of Presentation

3 Months Ended

Mar. 31, 2015

Basis of Presentation [Abstract]

Basis of Presentation

1.	Basis of Presentation

Our accompanying unaudited consolidated condensed financial statements as of March 31, 2015 and for the three months ended March 31, 2015 and 2014 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at March 31, 2015 has been derived from the audited financial statements at December 31, 2014, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the “Company”) have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. These financial statements should be read in conjunction with the Consolidated Financial Statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2014.

Use of Estimates

3 Months Ended

Mar. 31, 2015

Use of Estimates [Abstract]

Use of Estimates

2.	Use of Estimates

The preparation of Consolidated Condensed Financial Statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, valuing warrants, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the Joint venture, and valuing allowances for doubtful accounts and inventories.

Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the Consolidated Condensed Financial Statements in the periods they are determined to be necessary.

Capital Availability

3 Months Ended

Mar. 31, 2015

Capital Availability [Abstract]

Capital Availability

3.	Capital Availability

We incurred net losses of $22 million for the three months ended March 31, 2015 and $10.4 million for the three months ended March 31, 2014, respectively. We have an accumulated deficit of $360 million as of March 31, 2015. Additionally, we have used net cash of $5 million and $9 million to fund our operating activities for the three months ended March 31, 2015 and 2014, respectively. To date, these operating losses have been funded primarily from outside sources of invested capital and gross profits. On May 5, 2015, we entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25 million of units, with each unit consisting of its common stock and one warrant to purchase one share of its common stock.

Pursuant to the recently announced securities transaction and related equity issuance, as well as anticipated gross profits and potential outside sources of capital, the Compnay believes it has sufficient cash to fund operations through at least the next 18 months, which includes minimum liquidity requirements of the Loan and Security Agreement, which requires us to maintain at least three months of cash on hand. The Company continues to seek additional capital through product revenues, strategic transactions, including extension opportunities under the awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives.

Refer to note 12 for a discussion on our May 2015 financing.

Transactions with Olympus Corporation

3 Months Ended

Mar. 31, 2015

Transactions with Olympus Corporation [Abstract]

Transactions with Olympus Corporation

4.	Transactions with Olympus Corporation

The Company’s obligation to Olympus, for the purchase of our interest in the Joint venture, has yet to be settled, and accordingly, the obligation calls for $6.0 million in total payments to be made by May 8, 2015. Since we have made payments totaling $2.8 million through March 31, 2015, our remaining payment obligation under this option is now $3.2 million.

As a result of our quarterly reassessment, we have recorded additional interest expense of $0.2 million during the three months ended March 31, 2015, and have a remaining unrecognized future discount amount of approximately $0.1 million as of March 31, 2015.

On April 30, 2015, the Company entered into Amendment One to Joint Venture Termination Agreement (the “Amendment”) with Olympus Corporation (“Olympus”) to that certain Joint Venture Termination Agreement, dated May 8, 2013, by and between Cytori Therapeutics, Inc. and Olympus (the “Agreement”) in order to extend our payment obligations under the Agreement.

Under the Agreement, we are required to pay Olympus a total purchase price of $6 million within two years of the date of the Agreement. The Amendment amends the payment terms to extend the period for payment of the remaining balance of the $6 million, or $3.2 million, with the balance of the purchase price bearing an interest rate of 6% per annum. Pursuant to the amendment,we paid $1 million on May 8, 2015 and are required to pay $0.5 million of principal on or prior to September 30, 2015, $0.5 million of principal on or prior to December 31, 2015, $0.5 million of principal on or prior to March 31, 2016, and the remaining $0.7 million of principal and accrued interest on or prior to May 8, 2016. We may prepay the remaining principal and accrued interest at any time without penalty.

In accordance with the terms of the Agreement, if we fail to pay the full balance of any installment payment, we will be required to pay Olympus the extended purchase price of a total of $16 million on or prior to March 1, 2020, with any principal payments previously paid applied towards the extended purchase price.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Revenue Recognition

3 Months Ended

Mar. 31, 2015

Revenue Recognition [Abstract]

Revenue Recognition

5.	Revenue Recognition

Concentration of Significant Customers

One distributor and one direct customer comprised 50% of our revenue recognized for the three months ended March 31, 2015. One direct customer and two distributors accounted for 71% of total outstanding accounts receivable as of March 31, 2015.

Three distributors comprised 68% of our revenue recognized for the three months ended March 31, 2014. Two distributors accounted for 70% of total outstanding accounts receivable as of March 31, 2014.

Product revenues, classified by geographic location, are as follows:

	Three months ended

	March 31, 2015					March 31, 2014
	Product Revenues		% of Total			Product Revenues		% of Total

North America	$	136,000		15	%	$	175,000		17	%
Japan		605,000		67	%		644,000		62	%
Europe		89,000		10	%		212,000		21	%
Other countries		72,000		8	%		—		—
Total product revenues	$	902,000		100	%	$	1,031,000		100	%

Research and Development

We earn revenue for performing tasks under research and development agreements with governmental agencies like the BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $1.4 million in BARDA revenue for the three months ended March 31, 2015, as compared to $0.4 million for the three months ended March 31, 2014.

Inventories

3 Months Ended

Mar. 31, 2015

Inventories [Abstract]

Inventories

6.	Inventories

Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.

Inventories consisted of the following:

	March 31, 2015		December 31, 2014

Raw materials	$	1,733,000	$	1,715,000
Work in process		1,361,000		1,301,000
Finished goods		1,520,000		1,813,000
	$	4,614,000	$	4,829,000

Loss per Share

3 Months Ended

Mar. 31, 2015

Loss per Share [Abstract]

Loss per Share

7.	Loss per Share

Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented.

We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the three months ended March 31, 2015 and 2014, as their inclusion would be antidilutive. Potentially dilutive common shares excluded from the calculations of diluted loss per share were 40.1 million for the three months ended March 31, 2015 and 17.1 million for the three months ended March 31, 2014.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies [Abstract]

Commitments and Contingencies

8.	Commitments and Contingencies

We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of March 31, 2015, we have clinical research study obligations of $5.4 million ($3.7 million of which are expected to be complete within a year). Should the timing of the clinical trials change, the timing of the payment of these obligations would also change.

We have entered into several lease agreements for our headquarters office location as well as international office locations. As of March 31, 2015, we have remaining lease obligations of $5.7 million ($2.2 million of which are expected to be completed within a year).

We have amended a supply agreement that contains a minimum purchase requirement. Pursuant to the amendment, as of March 31, 2015, we have a minimum purchase obligation of $1 million, all of which is expected to be completed within a year.

We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.

Refer to note 4 for a discussion of our commitments and contingencies related to our transactions with Olympus.

Fair Value Measurements

3 Months Ended

Mar. 31, 2015

Fair Value Measurements [Abstract]

Fair Value Measurements

9.	Fair Value Measurements

Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below:

· Level 1: Quoted prices in active markets for identical assets or liabilities.

· Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

· Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.

The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:

	Balance as of March 31, 2015		Basis of Fair Value Measurements
	Balance as of March 31, 2015		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	6,144,000	$	6,144,000	$	—	$	—
Liabilities:
Warrant liability	$	25,237,000	$	—	$	—	$	25,237,000

	Balance as of December 31, 2014		Basis of Fair Value Measurements
	Balance as of December 31, 2014		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	8,144,000	$	8,144,000	$	—	$	—
Liabilities:
Warrant liability	$	9,793,000	$	—	$	—	$	9,793,000

We use quoted market prices to determine the fair value of our cash equivalents, which consist of money market funds that are classified in Level 1 in the fair value hierarchy.

Warrants with exercise price reset features (down-round protection) are accounted for as liabilities, with changes in the fair value included in net loss for the respective periods. Because some of the inputs to our valuation model are either not observable or are not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability is classified as Level 3 in the fair value hierarchy.

Our stock price can be volatile and there could be material fluctuations in the value of warrants in the future periods.

The following table summarizes the change in our Level 3 warrant liability value:

Warrant liability	Three months ended March 31, 2015

Beginning balance	$	9,793,000
Change in fair value		15,444,000
Ending balance	$	25,237,000

The main driver for the change in the fair value of warrants was 141% increase in our stock price at March 31, 2015, as compared to the stock price at December 31, 2014.

Fair Value

3 Months Ended

Mar. 31, 2015

Fair Value [Abstract]

Fair Value

10.	Fair Value

Financial Instruments

We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at March 31, 2015 and December 31, 2014, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.

We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available. If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.

At March 31, 2015 and December 31, 2014, the aggregate fair value and the carrying value of the Company’s fixed rate long-term debt were as follows:

	March 31, 2015				December 31, 2014

	Fair Value		Carrying Value		Fair Value		Carrying Value

Fixed rate long-term debt	$	25,466,000	$	25,630,000	$	25,206,000	$	25,373,000

Carrying value is net of debt discount of $1.2 million and $1.5 million as of March 31, 2015 and December 31, 2014, respectively.

The fair value of debt is classified as Level 3 in the fair value hierarchy as some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

3 Months Ended

Mar. 31, 2015

Stockholders' Equity [Abstract]

Stockholders' Equity

11.	Stockholders’ Equity

Preferred Stock

We have authorized 5 million shares of $0.001 par value preferred stock. Our Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock issued at March 31, 2015 and December 31, 2014 and 325 and 5,311 shares outstanding as of March 31, 2015 and December 31, 2014, respectively.

In October 2014, we entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company sold a total of 13,500 units for a purchase price of $1,000 per unit, with each unit consisting of one share of the Company’s Series A 3.6% Convertible Preferred Stock, which are convertible into shares of the Company’s common stock with a conversion price of $0.52, and warrants to purchase up to a number of shares of common stock equal to 100% of the conversion shares under the shares of preferred stock, in a registered direct offering. Each warrant has an exercise price of $0.5771 per share, is exercisable six months after the date of issuance and expires five years from the date on which it is initially exercisable. The preferred stock and the warrants were immediately separable and were issued separately. As of April 30, 2015, all remaining outstanding Series A 3.6% Convertible Preferred Stock were converted into shares of common stock. As of April 30, 2015, 8.5 million of the October 2014 warrants have been exercised at $0.5771 per share for gross proceeds of $4.9 million.

We recorded a dividend of $1.2 million for the year ended December 31, 2014, related to a beneficial conversion feature included in the issuance of our Series A 3.6% Convertible Preferred Stock. The fair value of the common stock into which the Series A 3.6% Convertible Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a dividend to the preferred shareholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common shareholders. Certain shares of Series A 3.6% Convertible Preferred Stock were not convertible until shareholder approval, which occurred in January 2015. As a result, additional dividends for the beneficial conversion feature of $0.7 million were recorded during the quarter ended March 31, 2015.

In connection with the 3.6% Convertible Preferred Stock outstanding at December 31, 2014, we declared a cash dividend of $ million. The cash dividend was paid in January 2015.

Common Stock

In May 2014, the Company entered into a sales agreement with Cowen and Company, LLC, relating to shares of our common stock, $0.001 par value per share. Pursuant to this agreement, during the quarter ended March 31, 2015, Cowen sold a total of 3.4 million shares of our common stock, raising approximately $4.2 million in gross proceeds (before deductions for fees and offering costs), through an “at the market offering.”

In September 2014, the Company and 13 holders of warrants dated June 4, 2014 to purchase a total of 4 million shares of the Company’s common stock agreed to amend the warrants in order to reduce the exercise price from $3.00 per share to $1.00 per share and change the expiration date from June 4, 2019 to September 10, 2014. The Company received proceeds of approximately $4 million from the exercise of the warrants. In addition, pursuant to the terms of the amendment, upon each holder’s exercise of all shares for cash prior to the amended expiration date, the Company issued additional warrants for the same number of common shares to the holders. The additional warrants have an exercise price of $2.00 per share, and are exercisable on the date that is six months and one day from the date of issuance and expire five years from the date of issuance. For those investors participating in the October 2014 issuance of Series A 3.6% Convertible Preferred Stock, we agreed to reduce the exercise price of 3.4 million warrants from $2.00 per share to $0.5771 per share, conditioned upon shareholder approval which was obtained in January 2015. As of March 31, 2015, there was a cashless exercise of 3.2 million warrants. As of April 30, 2015, the remaining 0.2 million warrants were exercised for proceeds of $0.1 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Subsequent Events

3 Months Ended

Mar. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

12.	Subsequent Events

In April, 2015, the Company’s exclusive licensee, Lorem Vascular Pte. Ltd., was granted regulatory clearance for the Cytori Celution® System by the State Food and Drug Administration of the People’s Republic of China (the “CFDA”). The CFDA clearance triggered certain purchasing obligations for Lorem Vascular, for Cytori Celution Devices and Cytori Celution Consumable Sets. Pursuant to the agreement, Lorem Vascular has submitted their initial purchase order upon receiving CFDA clearance.

On May 5, 2015, we entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25 million of units for a purchase price of $0.77 per unit, with each unit consisting of one share of the its common stock and one warrant to purchase one share of its common stock, in a registered direct offering. Each warrant will have an initial exercise price of $1.02 per share, will be exercisable six months after the date of issuance and expires five years from the date it becomes exercisable. The offering will have two separate closings, the first closing of $19.4 million took place on May 8, 2015 and the second close is subject to shareholder vote, which is anticipated to take place in August 2015.

Basis of Presentation (Policies)

3 Months Ended

Mar. 31, 2015

Basis of Presentation [Abstract]

Basis of Presentation

1.	Basis of Presentation

Use of Estimates (Policies)

3 Months Ended

Mar. 31, 2015

Use of Estimates [Abstract]

Use of Estimates

2.	Use of Estimates

Revenue Recognition (Policies)

3 Months Ended

Mar. 31, 2015

Revenue Recognition [Abstract]

Revenue Recognition

5.	Revenue Recognition

Concentration of Significant Customers

Three distributors comprised 68% of our revenue recognized for the three months ended March 31, 2014. Two distributors accounted for 70% of total outstanding accounts receivable as of March 31, 2014.

Product revenues, classified by geographic location, are as follows:

	Three months ended

	March 31, 2015					March 31, 2014
	Product Revenues		% of Total			Product Revenues		% of Total

North America	$	136,000		15	%	$	175,000		17	%
Japan		605,000		67	%		644,000		62	%
Europe		89,000		10	%		212,000		21	%
Other countries		72,000		8	%		—		—
Total product revenues	$	902,000		100	%	$	1,031,000		100	%

Research and Development

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2015

Revenue Recognition [Abstract]

Product Revenues by Geographic Location

Product revenues, classified by geographic location, are as follows:

	Three months ended

	March 31, 2015					March 31, 2014
	Product Revenues		% of Total			Product Revenues		% of Total

North America	$	136,000		15	%	$	175,000		17	%
Japan		605,000		67	%		644,000		62	%
Europe		89,000		10	%		212,000		21	%
Other countries		72,000		8	%		—		—
Total product revenues	$	902,000		100	%	$	1,031,000		100	%

Inventories (Tables)

3 Months Ended

Mar. 31, 2015

Inventories [Abstract]

Inventory

Inventories consisted of the following:

	March 31, 2015		December 31, 2014

Raw materials	$	1,733,000	$	1,715,000
Work in process		1,361,000		1,301,000
Finished goods		1,520,000		1,813,000
	$	4,614,000	$	4,829,000

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2015

Fair Value Measurements [Abstract]

Assets and Liabilities Measured at Fair Value

The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis:

	Balance as of March 31, 2015		Basis of Fair Value Measurements
	Balance as of March 31, 2015		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	6,144,000	$	6,144,000	$	—	$	—
Liabilities:
Warrant liability	$	25,237,000	$	—	$	—	$	25,237,000

	Balance as of December 31, 2014		Basis of Fair Value Measurements
	Balance as of December 31, 2014		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	8,144,000	$	8,144,000	$	—	$	—
Liabilities:
Warrant liability	$	9,793,000	$	—	$	—	$	9,793,000

Summary of Change in Level 3 Warrant Liablility

The following table summarizes the change in our Level 3 warrant liability value:

Warrant liability	Three months ended March 31, 2015

Beginning balance	$	9,793,000
Change in fair value		15,444,000
Ending balance	$	25,237,000

Fair Value (Tables)

3 Months Ended

Mar. 31, 2015

Fair Value [Abstract]

Fair Value and Carrying Value of Long-term Debt

At March 31, 2015 and December 31, 2014, the aggregate fair value and the carrying value of the Company’s fixed rate long-term debt were as follows:

	March 31, 2015				December 31, 2014

	Fair Value		Carrying Value		Fair Value		Carrying Value

Fixed rate long-term debt	$	25,466,000	$	25,630,000	$	25,206,000	$	25,373,000

Capital Availability (Details) - USD ($)			3 Months Ended
Capital Availability (Details) - USD ($)	May 08, 2015	May 05, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Oct. 31, 2014
Subsequent Event [Line Items]
Net loss			$ (21,958,000)	$ (10,400,000)
Accumulated deficit			(360,231,000)		$ (338,273,000)
Net cash used in operating activities			$ (5,030,000)	$ (8,962,000)
Common stock issued, value		$ 25,000,000
Institutional Investors [Member]
Subsequent Event [Line Items]
Each unit consist of number of common stock and warrant (in shares)						1
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock issued, value	$ 19,400,000
Each unit consist of number of common stock and warrant (in shares)		1
Subsequent Event [Member] \| Institutional Investors [Member]
Subsequent Event [Line Items]
Common stock issued, value		$ 25,000,000
Each unit consist of number of common stock and warrant (in shares)		1

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Transactions with Olympus Corporation (Details) - USD ($) $ in Millions			3 Months Ended
	May 08, 2015	Apr. 30, 2015	Mar. 31, 2015
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Payment totalling			$ 2.8
Remaining payment obligation			$ 3.2
Purchase price payment agreement term			2 years
Subsequent Event [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Total purchase price		$ 6.0
Amendment One to Joint Venture Termination Agreement [Member] \| Subsequent Event [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Purchase price remaining balance		$ 3.2
Interest rate on the purchase price of remaining balance (in hundredths)		6.00%
Purchase price principal amount payable on May 8, 2015		$ 1.0
Purchase price principal amount payable on September 30, 2015		0.5
Purchase price principal amount payable on December 31, 2015		0.5
Purchase price principal amount payable on March 31, 2016		0.5
Purchase price principal amount and accrued interest payable on May 8, 2016		$ 0.7
Acquired Olympus Ownership [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Additional interest expense			$ 0.2
Remaining Unrecognized Future Discount			0.1
Extended purchase price amount in default prior to March 1, 2020			$ 16.0
Acquired Olympus Ownership [Member] \| Subsequent Event [Member]
Acquisition of Olympus' Interest in the Joint Venture [Abstract]
Total payments to be made	$ 6.0

Revenue Recognition (Details)	3 Months Ended
Revenue Recognition (Details)	Mar. 31, 2015 USD ($) Distributor Customer	Mar. 31, 2014 USD ($) Distributor
Concentration Risk [Table]
Revenues	$ 902,000	$ 1,031,000
Concentration risk percentage (in hundredths)	100.00%	100.00%
Customer Concentration Risk [Member] \| Revenue Recognized [Member]
Concentration Risk [Table]
Number of distributors \| Distributor	1	3
Number of customers \| Customer	1
Concentration risk percentage (in hundredths)	50.00%	68.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Concentration Risk [Table]
Number of distributors \| Distributor	2	2
Number of customers \| Customer	1
Concentration risk percentage (in hundredths)	71.00%	70.00%
BARDA Contract [Member]
Research and Development Arrangements [Line Items]
Revenue recognized	$ 1,400,000	$ 400,000
North America [Member]
Concentration Risk [Table]
Revenues	$ 136,000	$ 175,000
Concentration risk percentage (in hundredths)	15.00%	17.00%
Japan [Member]
Concentration Risk [Table]
Revenues	$ 605,000	$ 644,000
Concentration risk percentage (in hundredths)	67.00%	62.00%
Europe [Member]
Concentration Risk [Table]
Revenues	$ 89,000	$ 212,000
Concentration risk percentage (in hundredths)	10.00%	21.00%
Other countries [Member]
Concentration Risk [Table]
Revenues	$ 72,000	$ 0
Concentration risk percentage (in hundredths)	8.00%	0.00%

Inventories (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Inventories [Abstract]
Raw materials	$ 1,733,000	$ 1,715,000
Work in process	1,361,000	1,301,000
Finished goods	1,520,000	1,813,000
Inventory, net	$ 4,614,000	$ 4,829,000

Loss per Share (Details) - shares shares in Millions	3 Months Ended
Loss per Share (Details) - shares shares in Millions	Mar. 31, 2015	Mar. 31, 2014
Loss per Share [Abstract]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	40.1	17.1

Commitments and Contingencies (Details) $ in Millions	Mar. 31, 2015 USD ($)
Recorded Unconditional Purchase Obligation [Line Items]
Minimum purchase obligations due within one year	$ 1.0
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase obligation	5.4
Purchase obligation, due in next twelve months	3.7
Operating Lease Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation	5.7
Contractual Obligation, due in next twelve months	$ 2.2

Fair Value Measurements (Details) - USD ($)	3 Months Ended
Fair Value Measurements (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Warrants [Member]
Change in Level 3 warrant liability [Roll Forward]
Percentage of increase in stock price (in hundredths)	141.00%
Fair Value, Measurements, Recurring [Member]
Assets [Abstract]
Cash equivalents		$ 6,144,000	$ 8,144,000
Liabilities [Abstract]
Warrant liability	$ 9,793,000	25,237,000	9,793,000
Change in Level 3 warrant liability [Roll Forward]
Beginning balance	9,793,000
Ending balance	25,237,000
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Cash equivalents		6,144,000	8,144,000
Liabilities [Abstract]
Warrant liability	0	0	0
Change in Level 3 warrant liability [Roll Forward]
Beginning balance	0
Ending balance	0
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Cash equivalents		0	0
Liabilities [Abstract]
Warrant liability	0	0	0
Change in Level 3 warrant liability [Roll Forward]
Beginning balance	0
Ending balance	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Cash equivalents		0	0
Liabilities [Abstract]
Warrant liability	9,793,000	25,237,000	9,793,000
Change in Level 3 warrant liability [Roll Forward]
Beginning balance	9,793,000
Ending balance	25,237,000
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Warrants [Member]
Liabilities [Abstract]
Warrant liability	9,793,000	$ 25,237,000	$ 9,793,000
Change in Level 3 warrant liability [Roll Forward]
Beginning balance	9,793,000
Change in fair value	15,444,000
Ending balance	$ 25,237,000

Fair Value (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fixed rate long-term debt	$ 25,466,000	$ 25,206,000
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fixed rate long-term debt	25,630,000	25,373,000
Debt discount	$ 1,200,000	$ 1,500,000

Stockholders' Equity (Details) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended	12 Months Ended
	May 05, 2015 $ / shares shares	Apr. 30, 2015 USD ($) shares	Oct. 31, 2014 $ / shares shares	Sep. 30, 2014 USD ($) WarrantHolder $ / shares shares	Mar. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	Sep. 10, 2014 $ / shares	Jun. 04, 2014 $ / shares
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares) \| shares					5,000,000
Preferred stock, par value (in dollars per share)					$ 0.001
Common Stock [Abstract]
Period exercisable from the date of issuance			6 months	6 months 1 day
Number of warrant holders \| WarrantHolder				13
Number of shares called by warrants (in shares) \| shares				4,000,000
Common stock, par value (in dollars per share)					$ 0.001	$ 0.001
Warrant exercise price (in dollars per share)				$ 2.00			$ 1.00	$ 3.00
Period in which warrants will expire				5 years
Warrant exercise price (in dollars per share)				$ 2.00			$ 1.00	$ 3.00
Warrants with reduced exercise price \| shares			3.4
Conversion price (in dollars per share)			$ 0.52
Percentage of shares equal to purchase of warrants (in hundredths)			100.00%
Cashless exercise of warrants \| $					$ 3,200
Proceeds from exercise of warrants \| $				$ 4,000
Subsequent Event [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $		$ 4,900
Period exercisable from the date of issuance	6 months
Number of shares called by warrants (in shares) \| shares		8,500,000
Warrant exercise price (in dollars per share)	$ 1.02
Period in which warrants will expire	5 years
Warrant exercise price (in dollars per share)	$ 1.02
Number of common stock and warrant available in each unit of subscription agreement (in shares) \| shares	1
Cashless exercise of warrants \| $		$ 200
Proceeds from exercise of warrants \| $		$ 100
Institutional Investors [Member]
Common Stock [Abstract]
Common stock issued (in shares) \| shares			13,500
Sale of stock, price per share (in dollars per share)			$ 1,000
Period in which warrants will expire			5 years
Number of common stock and warrant available in each unit of subscription agreement (in shares) \| shares			1
Institutional Investors [Member] \| Subsequent Event [Member]
Common Stock [Abstract]
Number of common stock and warrant available in each unit of subscription agreement (in shares) \| shares	1
Cowen and Company, LLC [Member]
Common Stock [Abstract]
Proceeds from private placement of stock \| $					$ 4,200
Common stock issued (in shares) \| shares					3,400,000
Common stock, par value (in dollars per share)					$ 0.001
Series A Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares) \| shares					5,000,000	5,000,000
Preferred stock, par value (in dollars per share)					$ 0.001	$ 0.001
Preferred stock, shares outstanding (in shares) \| shares					325	5,311
Preferred stock, shares issued (in shares) \| shares					13,500	13,500
Convertible preferred stock (in hundredths)					3.60%	3.60%
Common Stock [Abstract]
Warrant exercise price (in dollars per share)				$ 2.00
Warrant exercise price (in dollars per share)				$ 2.00
Series A Preferred Stock [Member] \| Dividend Declared [Member]
Common Stock [Abstract]
Dividends Payable \| $						$ 70
Series A Preferred Stock [Member] \| Dividend Paid [Member]
Common Stock [Abstract]
Dividends Payable \| $					$ 700	$ 1,200
Warrant liability [Member]
Common Stock [Abstract]
Warrant exercise price (in dollars per share)			$ 0.5771
Warrant exercise price (in dollars per share)			$ 0.5771

Subsequent Events (Details) $ / shares in Units, $ in Millions			1 Months Ended
	May 08, 2015 USD ($)	May 05, 2015 USD ($) Closing $ / shares shares	Oct. 31, 2014 shares	Sep. 30, 2014 $ / shares	Sep. 10, 2014 $ / shares	Jun. 04, 2014 $ / shares
Subsequent Event [Line Items]
Common stock issued, value \| $		$ 25.0
Exercise price of warrants (in dollars per share) \| $ / shares				$ 2.00	$ 1.00	$ 3.00
Period exercisable from the date of issuance			6 months	6 months 1 day
Period in which warrants will expire				5 years
Number of closings \| Closing		2
Institutional Investors [Member]
Subsequent Event [Line Items]
Each unit consist of number of common stock and warrant (in shares)			1
Period in which warrants will expire			5 years
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock issued, value \| $	$ 19.4
Each unit consist of number of common stock and warrant (in shares)		1
Exercise price of warrants (in dollars per share) \| $ / shares		$ 1.02
Period exercisable from the date of issuance		6 months
Period in which warrants will expire		5 years
Subsequent Event [Member] \| Warrant [Member]
Subsequent Event [Line Items]
Each unit consist of number of common stock and warrant (in shares)		1
Subsequent Event [Member] \| Institutional Investors [Member]
Subsequent Event [Line Items]
Common stock issued, value \| $		$ 25.0
Common stock at a purchase price (in dollars per unit) \| $ / shares		$ 0.77
Each unit consist of number of common stock and warrant (in shares)		1